Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2021 ASCRS member survey. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Chang, David F.; Rhee, Douglas J.
• Is Part Of: Journal of cataract and refractive surgery. Volume 48:Issue 1(2022)
• Page Start: 3
• Page End: 7
• Publication Date: 2022-01
• Subjects: 617.7
• DOI: 10.1097/j.jcrs.0000000000000757
• Languages: English
• ISSNs: 0886-3350

Abstract

Abstract : Intracameral antibiotic prophylaxis for cataract surgery increased to 66% of ASCRS members and would increase to 93% if an approved antibiotic became commercially available. Moxifloxacin is the leading preference. Abstract : In an online survey of >1200 global cataract surgeons, 66% were using intracameral (IC) antibiotic prophylaxis. This compared with 50% and 30% in the 2014 and 2007 surveys, respectively. Irrigation bottle infusion and intravitreal injection was each used by only 5% of respondents. For IC antibiotics, vancomycin was used by 6% in the United States (52% in 2014), compared with 83% for moxifloxacin (31% in 2014). Equal numbers used compounded moxifloxacin or the Vigamox bottle as the source. There was a decrease in respondents using preoperative (73% from 85%) and postoperative (86% from 97%) topical antibiotic prophylaxis; the latter was not used by 24% of surgeons injecting IC antibiotics. Reasons cited by those not using IC antibiotics include mixing/compounding risk (66%) and being unconvinced of the need (48%). However, 80% believe having a commercially approved IC antibiotic is important; if reasonably priced, this would increase adoption of IC prophylaxis to 93%.